Clinical trials of Intravenous Immunoglobulin for Alzheimer's disease

Journal of Clinical Immunology

Volumn 34, Issue SUPPL. 1, 2014, Pages

  Relkin, Norman ^a  

^a FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Clinical trials; Human intravenous immunoglobulin; Immunotherapy; Polyclonal IgG

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; IMMUNOGLOBULIN;

ALZHEIMER DISEASE; ANIMAL; CLINICAL TRIAL (TOPIC); COGNITION; DISEASE COURSE; DRUG EFFECTS; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEUROGENIC INFLAMMATION; PROCEDURES; PROTEIN DENATURATION; PROTEIN MULTIMERIZATION; TRENDS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN E4; CLINICAL TRIALS AS TOPIC; COGNITION; DISEASE PROGRESSION; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; NEUROGENIC INFLAMMATION; PROTEIN DENATURATION; PROTEIN MULTIMERIZATION;

EID: 84905184129     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-014-0041-4     Document Type: Article

References (23)

1. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12(10):383-8.
2. Schenk D et al. Immunization with amyloid-beta attenuates Alzheimer- disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-7. (Pubitemid 29327547)
3. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363-72.
4. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322-33.
5. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):311-21.
6. Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev. 2012;11(11):792-4.
7. Gaskin F, Finley J, Fang Q, et al. Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. J Exp Med. 1993;177:1181-6. (Pubitemid 23097407)
8. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57:801-5. (Pubitemid 32845498)
9. Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943-8. (Pubitemid 34665486)
10. Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol. 2001;49:808-10.
11. Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol. 2002;52:253-6. (Pubitemid 34810613)
12. Szabo P, Mujalli DM, Rotondi ML, et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol. 2010;227: 167-74.
13. O'Nuallain B, Williams AD, McWilliams-Koeppen HP, et al. Antiamyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol. 2010;30 Suppl 1:S37-42.
14. Ferreira ST, Klein WL. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem. 2011;96(4):529-43.
15. Enciu A, Popescu BO. Is there a causal link between inflammation and dementia? Biomed Res Int. 2013:ID: 316495. 1-6.
16. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009;30:1728-36.
17. Puli L, Pomeshchik Y, Olas K, et al. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation. 2012;9:105.
18. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75:1472-4. (Pubitemid 39279821)
19. Tsakanikas D, Relkin N. Neuropsychological outcomes following 18-months of uninterrupted intravenous immunoglobulin (IGIV) treatment in patients with Alzheimer's disease. Toronto: American Academy of Neurology; 2010.
20. Devi G, Schultz S, Khosrowshahi L, et al. A retrospective chart review of the tolerability and efficacy of intravenous immunoglobulin in the treatment of Alzheimer's disease. J Am Geriatr Soc. 2008;56:772-4. (Pubitemid 351473515)
21. Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013;12:233-43.
22. Relkin N, on behalf of the GAP Sttudy Group. Results of GAP (160701): a phase III study of intravenous gammaglobulin for the treatment of mild to moderate Alzheimer's disease. Presented at AAIC, Boston 2013.
23. Fillit H, Hess G, Hill J, et al. IVimmunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology. 2009;73(3):180-5.